RetinalGenix Technologies (RTGN) Non-Current Debt (2022 - 2026)
RetinalGenix Technologies (RTGN) reported Non-Current Debt of $49000.0 for Q1 2026, little changed sequentially from $49000.0 in Q4 2025.
RetinalGenix Technologies (RTGN) Non-Current Debt (2022 - 2026) Analysis & Trends
RetinalGenix Technologies (RTGN) has 4 years of Non-Current Debt data on file, last reported at $49000.0 in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Debt changed N/A year-over-year to $49000.0; the trailing twelve-month figure through Mar 2026 stood at $49000.0 (changed N/A YoY), and the FY2025 full-year result was $49000.0, changed N/A from the prior year.
- Non-Current Debt steadied at $49000.0 in Q1 2026, from $49000.0 in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $49000.0 in Q4 2022 to a low of $49000.0 in Q4 2022.
- A 4-year average of $49000.0 and a median of $49000.0 in 2022 frame the typical range for Non-Current Debt.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | 29.64 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 14.22 Bn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 26.17 Bn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 10.99 Bn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | 598.50 Mn |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | - |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | 10.13 Bn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | 3.18 Bn |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 8.07 Bn |
| 10 | RetinalGenix Technologies | 75.02 Mn | 75.02 Mn | - | 49,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 49,000.00 |
| Dec 31, 2025 | 49,000.00 |
| Sep 30, 2023 | 49,000.00 |
| Dec 31, 2022 | 49,000.00 |